Ampio

Ampio‪s Phase I Study for Inhaled Ampion Advances to Completing Enrollment of Covid-19 Patients With Respiratory Distress

Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology based therapies for prevalent inflammatory conditions, announced today that its AP-014 Phase I inhaled Ampion clinical study in COVID-19 patients is proceeding to full open enrollment following clearance by the Safety Monitoring Committee (SMC), which found Ampion to be safe...

Ampio‪s Phase I Study for Inhaled Ampion Advances to Completing Enrollment of Covid-19 Patients With Respiratory Distress

Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology based therapies for prevalent inflammatory conditions, announced today that its AP-014 Phase I inhaled Ampion™ clinical study in COVID-19 patients is proceeding to full open enrollment following clearance by the Safety Monitoring Committee (SMC).
Ampio Pharmaceuticals, Inc. 373 Inverness Parkway, Suite 200 Englewood, CO 80112 USA

+1 720 437 6500